Abstract:The discovery of hypoxia-inducible factor-1 has led to a rapidly increasing understanding of the molecular mechanism of tumor hypoxia in the past two decades. Today it is generally accepted that HIF-1 plays a pivotal role in the cellular response to tumor hypoxia which represents a major obstacle to the success of radiotherapy and chemotherapy. Meanwhile, many details involved in the expression, accumulation and transactivation of HIF-1 have been well elucidated. Targeting HIF-1 has become a novel and efficient strategy for cancer therapy and a number of agents have been developed aiming to suppress HIF-1. This review will concisely introduce the general knowledge on the molecular biology of HIF-1 and possible targets along the HIF-1 pathway. Moreover, a number of compounds reported with anti-HIF-1 activity are included and mainly classified as direct and indirect inhibitors based on their different modes of action. While direct HIF-1 inhibitors prevent HIF-1 from transactivation, DNA binding and subsequently initiating transcriptional activity, indirect HIF-1 inhibitors generally block the transcription or translation of HIF-1α or promote the degradation of HIF-1α protein. According to different structural features, direct HIF-1 inhibitors are divided into several groups: polyamides, quinols and naphthoquinone spiroketal analogues, shikonin derivatives, epidithiodiketopiperazines, and two representative drugs: echinomycin and bortezomib. In the same way, indirect inhibitors comprise the following classes: polyphenols, benzoazaheterocycles, rapamycins, camptothecins, geldanamycins, (aryloxyacetylamino)benzoic acid analogues, 2-methoxyestradiol and analogues, hydroxamic acid compounds and others. The rest with mechanism still not so clear would also be listed and introduced, with an emphasis on the marinederived natural products. The in vitro and/or in vivo activities of these compounds and their mechanisms of HIF-1 inhibition would be discussed and the SARs of unique structural types of HIF-1 inhibitors will be briefly concluded.

Recent Advances In The Discovery Of Hif-1 Alpha-P300/Cbp Inhibitors As Anti-Cancer Agents

Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents.

Advances in the HIF-1 Alpha/p300 Protein-Protein Interaction Inhibitors

Recent Agents Targeting Hif-1 Alpha For Cancer Therapy

Targeting Hypoxia-Inducible Factor-1, for Cancer Treatment: Recent Advances in Developing Small-Molecule Inhibitors from Natural Compounds.

Hypoxia Inducible Factor-1 alpha: A New Anticancer Drug Target

Advances in the research and development of HIF-1 inhibitors

Cancer Therapeutic Agents Targeting Hypoxia-Inducible Factor-1

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy

Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents

Recent Progress in the Study on Antitumor Drugs Targeting Hypoxia-Inducible Factor-1

Current development of CBP/p300 inhibitors in the last decade

Discovery of Highly Potent, Selective, and Orally Efficacious P300/cbp Histone Acetyltransferases Inhibitors

Action Sites and Clinical Application of HIF-1α Inhibitors

The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy

Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors

Recent Advances in the Study of Bioreductive Drugs Targeted Tumor Hypoxia

CBP/p300 bromodomain: new promising epigenetic target

Targeting CBP and p300: Emerging Anticancer Agents

Cancer Therapy by Targeting Hypoxia-Inducible Factor-1.

Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A “structure-activity relationship” perspective